CA Patent

CA2941594C — Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof

Assigned to Celera Corp · Expires 2021-07-06 · 5y expired

What this patent protects

ABSTRACT The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to the single polynucleotide polymorphism hCV25620145 in the protein C receptor (PROCR) gene and the disc…

USPTO Abstract

ABSTRACT The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to the single polynucleotide polymorphism hCV25620145 in the protein C receptor (PROCR) gene and the discovery that it is predictive of increased risk for myocardial infarction. The invention further pertains to nucleic acid rnolecules containing said polymorphism, variant proteins encoded by such nucleic acid molecule, reagents for detecting the polymorphic nucleic acid molecule and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Drugs covered by this patent

Patent Metadata

Patent number
CA2941594C
Jurisdiction
CA
Classification
Expires
2021-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Celera Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.